Data gathered: October 17
Alternative Data for ARS Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 24,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,894 | Sign up | Sign up | Sign up |
| Twitter Followers | 450 | Sign up | Sign up | Sign up |
| Twitter Mentions | 25 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 66 | Sign up | Sign up | Sign up |
| Linkedin Employees | 106 | Sign up | Sign up | Sign up |
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
| Price | $16.13 |
| Target Price | Sign up |
| Volume | 963,410 |
| Market Cap | $1.48B |
| Year Range | $7.01 - $16.52 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 1-Year High - Still a Buy?October 16 - Biztoc.com |
 |
ARS Pharmaceuticals, Inc. is on the Move, Here's Why the Trend Could be SustainableOctober 14 - Biztoc.com |
 |
Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to TradeOctober 13 - Yahoo |
 |
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal Sells 100,000 SharesOctober 13 - ETF Daily News |
|
SG Americas Securities LLC Cuts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)October 12 - ETF Daily News |
 |
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Dimensional Fund Advisors LPOctober 12 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '24 | 500,000 | 110,000 | 390,000 | -13M | 0 | -0.130 |
| Q1 '24 | 0 | 93,000 | -93,000 | -10M | -13M | -0.110 |
| Q4 '23 | 0 | -40M | 40M | -7.2M | -10M | -0.070 |
| Q3 '23 | 0 | 15M | -15M | -15M | -18M | -0.160 |
| Q2 '23 | 10,000 | 13M | -13M | -17M | -21M | -0.180 |
Insider Transactions View All
| Lowenthal Richard E filed to sell 1,348,499 shares at $13.8. October 10 '24 |
| Tanimoto Sarina filed to sell 1,348,499 shares at $13.8. October 10 '24 |
| Karas Eric filed to sell 5,693 shares at $14. September 19 '24 |
| Lowenthal Richard E filed to sell 1,398,499 shares at $12.9. September 19 '24 |
| Tanimoto Sarina filed to sell 1,398,499 shares at $12.9. September 19 '24 |
Similar companies
Read more about ARS Pharmaceuticals (SPRY) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of ARS Pharmaceuticals?
The Market Cap of ARS Pharmaceuticals is $1.48B.
What is the current stock price of ARS Pharmaceuticals?
Currently, the price of one share of ARS Pharmaceuticals stock is $16.13.
How can I analyze the SPRY stock price chart for investment decisions?
The SPRY stock price chart above provides a comprehensive visual representation of ARS Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ARS Pharmaceuticals shares. Our platform offers an up-to-date SPRY stock price chart, along with technical data analysis and alternative data insights.
Does SPRY offer dividends to its shareholders?
As of our latest update, ARS Pharmaceuticals (SPRY) does not offer dividends to its shareholders. Investors interested in ARS Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ARS Pharmaceuticals?
Some of the similar stocks of ARS Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.